TECP
ACAD icon

Trails Edge Capital Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Trails Edge Capital Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,419,406
Closed -$37.9M – 28
2025
Q4 		$37.9M Buy
+1,419,406
New +$33.9M 9.37% 1

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Trails Edge Capital Partners's ACAD Position: Q1 2026 in Review

Trails Edge Capital Partners sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 1,419,406 shares — an estimated $37.9M sold.

Trails Edge Capital Partners first reported a position in ACAD in Q4 2025 and held it in 1 quarter. The position peaked at $37.9M in Q4 2025. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Trails Edge Capital Partners reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Trails Edge Capital Partners sold 1,419,406 Acadia Pharmaceuticals shares in Q1 2026, an estimated $37.9M.
  • Trails Edge Capital Partners first reported a position in Acadia Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Trails Edge Capital Partners's Acadia Pharmaceuticals position peaked at $37.9M in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Trails Edge Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.